NSEGeneral Updates7 Sept 2026 · 7 Sept 2026, 08:34 pm

General Updates

Alembic Pharmaceuticals Limited · APLLTD

✦ AI SummaryExpansion

Alembic Pharmaceuticals Limited has informed the Exchange about the incorporation of a Wholly Owned Subsidiary (WOS) named Alembic Pharmaceuticals Global FZCO in Dubai, United Arab Emirates. The intimation was received on 7th September, 2026.

Analysis Scores

Earnings Impact5/10
Growth Catalyst6/10
Governance Concern2/10
Regulatory Risk3/10
Balance Sheet Risk4/10
Liquidity Impact7/10
Market Sentiment5/10

✦ Ask a Question

Ask anything about this announcement — AI will answer based on the filing content.

0/500

Full Announcement

Alembic Pharmaceuticals Limited has informed the Exchange about General Updates: : Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 - Incorporation Of a Wholly Owned Subsidiary Company

Attachments (1)

📄

APLLTD_07092026203031_APL_Intimation_Alembic_Pharmaceuticals_Global_FZCO_Signed.pdf

pdf

Download →
View document text
Date: 7th September, 2026 To, To, The Manager, The Manager, Department of Corporate Services, Listing Department, BSE Limited National Stock Exchange of India Ltd. P. J. Towers, Dalal Street, ‘Exchange Plaza’, Bandra Kurla Complex, Fort, Mumbai – 400 001 Bandra (E), Mumbai – 400 051 Scrip Code:533573 NSE Symbol: APLLTD Dear Sir/Madam, Sub: Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (‘Listing Regulations’) With reference to the captioned matter, we wish to inform you that a Wholly Owned Subsidiary (‘WOS’) of the Company, named Alembic Pharmaceuticals Global FZCO has been incorporated in Dubai, United Arab Emirates, on 24th August, 2026. The intimation regarding the incorporation of the said WOS was received by the Company on 7th September, 2026. The details required to be disclosed under in this regard as per Regulation 30 of the Listing Regulations, read with SEBI Master Circular No. HO/49/14/14(7)2025-CFD- POD2/I/3762/2026 dated January 30, 2026 (‘Master Circular’), are enclosed herewith as Annexure – I. We request you to kindly take the same on record. Thanking you, Yours faithfully, For Alembic Pharmaceuticals Limited Chirag K. Shukla Company Secretary Encl: A/a ALEMBIC PHARMACEUTICALS LIMITED REGD. OFFICE: ALEMBIC ROAD, VADODARA - 390 003. ● TEL: (0265) 2280550, 2280880 ● FAX: (0265) 2281229 Website : www.alembicpharmaceuticals.com ● E-mail : alembic@alembic.co.in ● CIN : L24230GJ2010PLC061123 Annexure-I The details required to be disclosed under Regulation 30 of Listing Regulations, as specified in Clause 1.1.A of Annexure-18 of the Master Circular: Particulars Details i. Name of the entity, date & Name of the entity: Alembic Pharmaceuticals country of incorporation, etc.; Global FZCO Date of Incorporation: 24th August, 2026 Country of Incorporation: United Arab Emirates ii. Name of holding company of Name of the Holding Company: Alembic the incorporated company Pharmaceuticals Limited and relation with the listed entity Relation with the Company: Wholly Owned Subsidiary iii. Industry to which the entity Pharmaceuticals being incorporated belongs; iv. Brief background about the To explore new business opportunities and to entity incorporated in terms promote, sale and distribute pharmaceutical of products / line of product(s) of the Company. business v. Brief details of any Not Applicable governmental or regulatory approvals required for the incorporation; vi. Nature of consideration - Cash consideration whether cash consideration or share swap and details of the same vii. Cost of subscription / price at Cost of Subscription: AED 100,000 (Arab which the shares are Emirates Dirham One Lakh Only). subscribed Price: 100 shares of AED 1,000 each are subscribed. viii. Percentage of shareholding / Percentage of shareholding: 100% control by the listed entity and / or number of shares allotted No. of shares allotted: 100 shares of AED 1,000 each ALEMBIC PHARMACEUTICALS LIMITED REGD. OFFICE: ALEMBIC ROAD, VADODARA - 390 003. ● TEL: (0265) 2280550, 2280880 ● FAX: (0265) 2281229 Website : www.alembicpharmaceuticals.com ● E-mail : alembic@alembic.co.in ● CIN : L24230GJ2010PLC061123